Vergallo, A;
Megret, L;
Lista, S;
Cavedo, E;
Zetterberg, H;
Blennow, K;
Vanmechelen, E;
... Younesi, E; + view all
(2019)
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.
Alzheimer's & Dementia
, 15
(6)
pp. 764-775.
10.1016/j.jalz.2019.03.009.
Preview |
Text
Zetterberg_Vergallo.pdf - Accepted Version Download (574kB) | Preview |
Abstract
Introduction: Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. / Methods: We investigated whether plasma concentrations of the Aβ1–40/Aβ1–42 ratio, assessed using the single-molecule array (Simoa) immunoassay, may predict brain Aβ positron emission tomography status in a large-scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis-driven investigation followed by a no-a-priori hypothesis study using machine learning. / Results: The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ1–40/Aβ1–42 ratio. The accuracy is not affected by the apolipoprotein E (APOE) ε4 allele, sex, or age. / Discussion: Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ1–40/Aβ1–42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design.
| Type: | Article |
|---|---|
| Title: | Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jalz.2019.03.009 |
| Publisher version: | https://doi.org/10.1016/j.jalz.2019.03.009 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Alzheimer's disease, Plasma amyloid β, Simoa immunoassay, Machine learning, Subjective memory complainers, Amyloid PET, Classification and regression trees (CART) |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10077029 |
Archive Staff Only
 |
View Item |
